Abiopharma

CytomX Therapeutics Inc (CTMX) Announces Clinical Trial Update CytomX Therapeutics Inc (CTMX) provided an update on its clinical development programs. Clinical Development Highlights:

• Collaboration: Registrant’s Telephone Number, Including Area Code
  • anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the potential benefits, safety and efficacy or progress of the Company’s or any of its collaborative partners’ product candidates, including praluzatamab ravtansine, the Company’s ability to develop and advance product candidates into and successfully complete clinical trials, including the ongoing clinical trial of praluzatamab ravtansine, the timing of ongoing data availability and the Company’s ability to obtain a partner for praluzatamab ravtansine. Other important risks and uncertainties are detailed in the Company’s reports and other filings with the Securities and Exchange Commission, including its most recent Quarterly Report on Form 10-Q. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934